Inclusion Criteria:

- Is at least 20 years of age

- Is referred for a contrast-enhanced MRI of the body/extremities based on current
clinical symptoms or results of a previous imaging procedure

- Is willing to undergo the routine contrast-enhanced MRI examinations

- Is willing and able to complete all study procedures specified in the protocol

- Subject is male, or is female not of childbearing potential, or is female of
childbearing potential who is using any medically accepted means of contraception and
has a negative urine pregnancy test prior to the administration of gadobutrol or
Magnevist

Exclusion Criteria:

- Is a female subject who is pregnant or nursing

- Has received any investigational product or has participated in any other clinical
trial within 2 weeks prior to enrolling in this study

- Has been previously enrolled in this study or any other study using gadobutrol

- Has any contraindication to the MRI examinations or the use of Gd-containing contrast
agents

- Has a history of severe allergic or anaphylactoid reaction to any allergen including
drugs and contrast agents

- Has received any contrast agent within 24 hours prior to the study MRI

- Has a glomerular filtration rate value <30 mL/min/1.73m2 derived from a serum
creatinine result within 4 weeks prior to study enrollment

- Is considered clinically unstable or his/her clinical course during the study period
is unpredictable (eg, due to previous surgery, acute renal failure)

- Has severe cardiovascular disease (eg, acute myocardial infarction (<14 days),
unstable angina, congestive heart failure New York Heart Association class IV) or
acute stroke (<48 hours)

- Patients with acute renal insufficiency of any severity due to hepato-renal syndrome
or in the perioperative liver transplantation period

- Has any contraindication to Magnevist according to the package insert